factor (N-TEF), which consists of the negative elongation factor and DRB-sensitive inducing factor [7] . To overcome the transcriptional block caused by N-TEF, Tat binds to the transactivation-responsive element (TAR), a short nucleotide stem loop located at the 5 0 -end of all HIV transcripts [4] . Following TAR binding, Tat recruits the positive transcription elongation factor (P-TEFb) complex, which is composed of CyclinT1 and CDK9. As a kinase subunit of the P-TEFb complex, CDK9 phosphorylates the C-terminal domain of RNA polymerase II (RNAPII) at serine-2, releasing the paused RNAPII from the promoter-proximal region and increasing processivity of RNAPII to transcribe the full-length virus [8, 9] . Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like (APOBEC) 3G and 3F (A3G and A3F) were recently shown to inhibit HIV-1 and hepatitis B virus (HBV) reverse transcription in the absence of the viral infectivity factor (Vif) [10] [11] [12] . Another APOBEC protein, activation-induced cytidine deaminase (AID), is an essential enzyme for class switch recombination (CSR) and somatic hypermutation in B cells. AID has been reported to inhibit the HBV, retro-transposons and Kaposi's sarcoma-associated herpesvirus, the cause of Kaposi's sarcoma, which commonly occurs in AIDS patients [13] [14] [15] [16] [17] [18] [19] [20] . However, whether AID can inhibit HIV-1 remains unclear. In this study, we show that AID recruits the RNA exosome to repress ongoing HIV-1 transcription via the HIV-1 Tat protein.
Results

AID suppresses HIV-1 transcripts
To determine whether AID can suppress HIV-1, we employed two reporter viruses ( Fig. S1A ): a luciferase reporter virus, pNL4.3.Luc (luciferase is inserted inframe into nef) and pNL4.3.DE.GFP (GFP is inserted in-frame into env). After cotransfection with pNL-4-3-Luc and a secreted alkaline phosphatase (pSEAP) construct into 293T cells, AID expression significantly reduced the levels of HIV-1 RNA and corresponding luciferase activity, whereas A3G had no effect (Fig. 1A) . A3G did not affect the HIV-1 RNA level because reverse transcription is not required in producer cells. In this experiment, we combined the pSEAP construct with pNL4-3-Luc to exclude the possibility that the inhibition of HIV-1 by AID was due to cell stress or toxicity. Moreover, the AID mutant P20 [21, 22] , with a 34-residue insertion at the carboxyl terminus, did not significantly inhibit HIV-1. Interestingly, P19 [21, 22] , the catalytically dead mutant with a point mutation at the H56Y position, significantly inhibited HIV-1 like wild-type AID. These data also indicate that the inhibition of HIV-1 was not due to cell stress or toxicity, but more likely induced by AID deamination activity. To verify this observation, we cotransfected the HIV-1 proviral vector pNL4-3, carrying a full-length HIV-1 sequence, into 293T cells with various combinations of plasmids encoding wildtype or mutant human AID (hAID), mouse AID (mAID), or A3G. Intracellular HIV-1 transcripts and extracellular virions were determined, respectively (Fig. S1B, C) . Both hAID and mAID significantly decreased HIV-1 transcripts and the HIV-1 nucleocapsid. Mouse AID with GFP at the C-terminal resulted in a similar inhibition, which was abrogated with EGFP at the N-terminal. These data suggest that the intact N-terminal of AID may be critical for anti-HIV activity. Moreover, we electroporated the HIV-1 provirus pNL4-3 into activated CD4 + T cells along with various combinations of constructs encoding AID or its mutants. Both AID and P19 vectors suppressed HIV-1 transcripts in CD4 + T cells (Fig. 1B) . To determine whether AID downregulates nascent HIV-1 transcripts as it does HBV [20] , we employed a nuclear run-on assay. The 5 0 -ethynyl uridine (EU) labeled HIV-1 nascent RNA was significantly suppressed by both AID and P19 in CD4 + T cells (Fig. 1C) . Subsequently, we sequenced the RNA samples from Fig. 1A , and determined that AID did not deaminate RNAs in samples transfected with pNL4-3-Luc plasmid DNA (Fig. S1D) , suggesting that editing of the cotransfected pNL4-3-Luc plasmid DNA by AID did not occur in our system. When AID or A3G were expressed with a plasmid encoding Vif in 293T cells [23, 24] , AID was not affected, unlike A3G (Fig. S1E) . Moreover, in agreement with previous studies [25] , we also found that AID was incorporated into HIV-1 virions (Fig. S1F ). Since Vif does not affect AID expression and the P19 mutant has no enzymatic activity, we further evaluated the potential roles of P19 in gene therapy. We individually electroporated P19-GFP or Mock (GFP) expression vectors into human peripheral blood mononuclear cells (PBMCs) isolated from 32 HIV-1 patients not receiving combination antiretroviral therapy (cART) treatment. After 48 h of stimulation, we sorted the GFP-positive cells and extracted total RNA for qRT-PCR measurement of HIV-1 Gag transcripts (Fig. 1D) . Transient delivery of the P19 gene suppressed HIV-1 transcripts in PBMCs from all patients. Since P19 is a catalytically dead mutant of AID, which cannot induce cellular genome mutations or instability [16, [20] [21] [22] , this result suggests that P19 may be used as a safe tool in gene therapy against HIV-1 replication.
AID may target integrated HIV-1 virus
Although cART treatment greatly inhibits HIV-1 replication in infected patients, it cannot affect the integrated virus. To determine whether AID can target the integrated, latent virus, we used 3TC (Lamivudine) to inhibit reverse transcription after HIV-1 NL4.3.DE.GFP infection ( Fig. 2A) . The unintegrated viral cDNA was not detected after 6 days (Fig. 2B) . Chromatin immunoprecipitation assays were used to determine that AID binds at HIV-1-TAR and POL (Fig. 2C, D) , but not nontarget THY1.1. Strikingly, the occupancy of RNAPII at HIV-1-TAR and POL was drastically reduced by the presence of AID, whereas RNAPII binding with THY1.1 was not affected, suggesting that AID may recognize and target integrated HIV-1 viral genomes.
AID recruits the RNA exosome to degrade HIV-1 transcripts Next, we examined the molecular mechanism of AIDmediated suppression of HIV-1 transcripts. The RNA exosome has been shown to bind to AID, causing the cleavage of nascent RNA of immunoglobulins and HBV [20, [26] [27] [28] . Thus, we hypothesized that AID may also act as an adaptor that recruits the RNA exosome . Following 48 h stimulation with PHA and IL2, GFP+ cells were further sorted and total RNA was extracted. HIV-1 RNA was measured by qRT-PCR and normalized to GAPDH (the mean of mock was set as 1). The data represent mean AE standard error calculated from triplicate measurements and were analyzed by t-test. *P < 0.05, **P < 0.01, ***P < 0.001, NS not significant.
to degrade HIV-1 RNA transcripts in a deaminase activity-independent manner. To test this hypothesis, we performed knockdown assays with siRNA against two exosome components: Rrp40 (EXOSC3), the core subunit and Mtr3 (EXOSC6), the catalytic subunit. Either Rrp40 or Mtr3 knockdown partially restored Gag RNA levels in the presence of AID (Fig. 3A) , whereas knockdown had no effect in the absence of AID. Furthermore, RNA immunoprecipitation (IP) with an anti-Rrp40 antibody only included HIV-1 RNA in the presence of AID (Fig. 3B) . As a putative substrate of the RNA exosome, DNA methyltransferase 1 (DNMT1) transcripts [29] were immunoprecipitated in an AID-independent manner while the transcripts of GAPDH, a nontarget of neither AID nor the RNA exosome, were absent from IP products. Moreover, the AID protein was detected in Rrp40 IP ( Fig. 3C ), suggesting interaction with HIV-1 RNA. Collectively, these data indicate that the RNA exosome may be responsible for AID-mediated degradation of HIV-1 transcripts and that the interaction between RNA exosome and HIV-1 transcripts is dependent on the presence of AID.
HIV-1 TAR structure and Tat protein are critical for AID-mediated suppression of HIV-1 transcripts Furthermore, we studied how AID recruits the RNA exosome to HIV-1 transcripts. TAR RNA is located at the 5 0 -end of all viral transcripts and stimulates the transcription and elongation of HIV-1 transcription by interacting with the Tat-P-TEFb complex [3, 5, 30] . To specifically block TAR, we employed ssDNA aptamers [31, 32] to interfere with the binding of Tat to TAR (Fig. 4A) . The core sequence of IV-04, 'ACTCCCAT', is critical for blocking TAR by forming RNA-DNA 'kissing loop complexes' without disrupting the secondary structure. In the IV-04-mut aptamer, the core nucleotide sequence was randomized to 'CCATACTC' To evaluate the suppression of HIV-1 transcripts by AID, aptamer IV-04 was used at dosages that would not dramatically affect Tat-mediated transcription. At higher dosages, IV-04 abrogates Tat-mediated transcription. With IV-04, there was a slight suppression of HIV-1 transcripts in the absence of AID, likely because the blockade of TAR inhibits Tat transactivating de novo transcription (Fig. 4B) . However, in the presence of AID, IV-04 significantly rescued the expression of both luciferase and HIV-1 RNA. These effects were seen with neither IV-04-mut nor I-06 (a negative control). None of the DNA aptamers affected the RNAs of TAR-lacking HBV in the presence or absence of AID (Fig. 4C) , which indicates the specific effects of AID on HIV-1 TAR. Since TAR is recognized and specifically bound by HIV-1 Tat, we next examined the roles of Tat in the anti-HIV-1 activity of AID. Transfection of anti-Tat antibody into 293T cells, to deplete Tat, abrogated AID-mediated HIV-1 luciferase suppression (Fig. 5A) , but had no effect on Chromatin immunoprecipitation assays were performed 72 h later using anti-FLAG or RNAPII antibodies as well as IgG. qPCR was used to measure precipitated DNA fragments. Data represent mean AE standard error calculated from triplicate measurements and were analyzed by t-test.
HBV RNA (Fig. 5B) . Notably, Tat and P-TEFb (CycT1 and CDK9) cooperatively bind to TAR and their conserved RNP complex is essential for HIV-1 transcription elongation [33] . Knockdown of CycT1 interrupted HIV-1 de novo transcription as expected, but also diminished the ability of AID to suppress HIV expression (Fig. 5C ). Taken together, these data demonstrate that Tat-CycT1-CDK9-TAR RNP complex formation at the HIV-1 promoter 5 0 LTR is important for AID-mediated suppression of HIV-1 RNA.
AID associates with HIV-1 Tat
Next, we investigated the interaction between Tat and AID by performing Co-IP assays with anti-Tat antibodies to further characterize the involvement of Tat with AID. The Tat protein was pulled down in 293T cells cotransfected with AID or GFP constructs along with pNL4.3.Luc (Fig. 6A) . As expected, AID, but not GFP, immunoprecipitated with Tat. The reciprocal FLAG IP experiment showed that Tat bound to AID, but not to A3G (Fig. 6B) , suggesting that AID, but not A3G, binds to the Tat-P-TEFb-TAR RNP complex. Interestingly, the interaction between Tat and AID does not appear to be dependent on HIV-1 because Tat interacted with AID in the absence of HIV-1 molecules (Fig. 6C) . We furthermore observed that the interaction between AID and P-TEFb does not rely on the presence of Tat. The AID associates with the P-TEFb complex in 293T, BL2 and stimulated splenic mouse B cells (Fig. S2A-C) , suggesting that P-TEFb may act as a bridge between AID and viral Tat during HIV-1 replication.
Discussion
This study sheds light on the mechanism by which AID inhibits HIV-1 transcription. AID possesses a unique antiviral mechanism, as summarized in Fig. S3 , that is quite different from that of A3G. The proposed mechanism suggests that AID is a unique antiviral agent with the advantage of virus restriction, unlike previously reported antiviral proteins such as A3G. AID suppresses wild-type HIV-1, which is not antagonized by Vif or Tat. Tat promotes, and is critical for, the anti-HIV-1 activity of AID. Moreover, given that the catalytically dead AID mutant, P19, also had an anti-HIV-1 effect and is a small moiety (24 kDa, 198 amino acids), P19 may be suitable for use in gene therapy to suppress HIV-1 replication while avoiding wild-type AID deamination-mediated cellular genome instability.
We recently reported that AID is induced by IL-1 and TGF-b1 in hepatocytes to suppress HBV infection The data represent mean AE standard error calculated from triplicate measurements and were analyzed by t-test. *P < 0.05, **P < 0.01. [14, 20] . However, endogenous AID expression was not detected in either activated or resting CD4 + T cells (data not shown). Since P-TEFb also binds to endogenous AID in both human and mouse B cells, we were curious whether the P-TEFb complex is involved in the physiological activity of AID. To examine whether P-TEFb associates with AID to promote CSR, we briefly explored the potential roles of P-TEFb in mouse B cells. Depletion of either CycT1 or CDK9 inhibited AID-mediated CSR, but did not significantly affect germline transcript levels (Fig. S4A) . Moreover, P-TEFb and AID bound to the region Sl switch region in activated mouse B cells (Fig. S4B) . These data indicate that the P-TEFb complex may be a physiological cofactor of AID in B cells. In contrast, during HIV-1 infection, AID may take advantage of the P-TEFb complex hijacked by Tat to repress HIV-1 transcription through recruitment of RNA nucleases. Notably, in addition to PTEFb, other TAR-interacting proteins, such as TAR RNA-binding protein (TRBP) and High Mobility Group AT-hook 1 (HMGA1) differentially modulate HIV-1 transcription [34] [35] [36] . The TRBP cooperates with Tat to promote viral transcription, whereas HMGA1 competes with Tat to inhibit viral transcription. In contrast, AID functions as an adaptor between RNA exosomes and HIV-1 transcripts through viral Tat. RNA exosome-mediated cleavage is likely responsible for the anti-HIV-1 activity of AID. Thus, the anti-HIV activity of AID may not involve either HMGA1 or TRBP. Taken together, the antiviral activity of AID may be widespread, and future studies are required to determine whether endogenous AID is induced to physiologically suppress HIV-1 replication in host cells. PBMCs were isolated from 20 mL of whole blood from HIV-1 seropositive by using Ficoll-Hypaque (Amersham, Pittsburgh, PA, USA) gradients. Electroporation was performed using a Lonza Amaxa nucleofector according to the manufacturer's instructions. Next, 4 9 10 6 PBMC were gently mixed with 100 lL human primary T-cell buffer (Lonza, Walkersville, MD, USA) and 2 lg expression vectors. The electroporation program was set as U-014. ). Mouse primary B cells were isolated and cultured as previously described [13] . Mouse primary B cells were first stimulated with LPS for 24 h, and then electroporated with siRNA. At 6 h after electroporation, IL4 was added to media for 48 h. Plasmids or siRNAs were transfected with Lipofectamine 2000 according to the manufacturer's instructions (Invitrogen, Waltham, MA, USA).
Ethics statement
Reagents
Human IL-2 and PHA were purchased from R&D systems (Minneapolis, MN, USA) and Sigma-Aldrich (St. Louis, MO, USA).
Nuclear run-on
Cells were cultured with ongoing RNA labeling reagent EU (Life technology C10365) for 1 h. Total RNA was extracted and treated with biotin azide which reacts with EU in the nascent RNA. Then, the biotin labeled nascent RNA was enriched by Dynabeads according to manufacturer's instructions. Nascent RNA levels were measured by qRT-PCR.
Luciferase and SEAP detection assay
The luciferase activity (Promega, Madison, WI, USA) in the cell lysates and the SEAP activity (Clontech, Dalian, China) in the culture supernatants were measured according to the manufacturer's instructions.
Southern blotting and PIC complex extraction
293T cells were infected with pNL4-3-DEGFP (VSV-G) for 1 day and lamivudine (at 50 lM) was added to inhibit reverse transcription. The cells were cultivated for the times indicated. HIV-1 cDNA was extracted and southern blotting was performed as described previously [37] .
HBV DNA extraction
Cytoplasmic HBV nucleocapisd DNA was extracted and analyzed as described previously [16, 20] .
Extracellular HIV-1 virion RNA measurement HIV-1 RNA was measured through real-time polymerase chain reaction (RT-PCR) using the COBASAmpliPrep/ COBAS TaqMan (Roche Diagnostic Systems, Rotkreuz, Switzerland). The detection range of the assay was 20-10 000 000 cpÁmL À1 . HIV-1 RNA copy numbers were calculated according to the manufacturer's reference standards.
Antibody transfection
Antibodies against Tat or control IgG (2 lg) were transfected into 293T cells according to the manufacturer's instructions (Xfect Protein Transfection Reagent; Clontech).
ChIP
Cells were cross-linked with 1% formaldehyde for 10 min at 37°C and the cross-linking was stopped by addition of 0.125 M glycine, followed by washing with cold PBS and lysis in 0.2 mL of SDS lysis buffer per 10 million cells. After incubation on ice for 20 min, the cell suspension was sonicated until the size of most DNA fragments was between 100 and 800 bp. The sonicated solution was diluted with ChIP dilution buffer to a volume of 1 mL. Sheared DNA was centrifuged at 14 000 g for 15 min at 4°C to remove cell debris, followed by preclearing for 2-6 h at 4°C with 50 lL IgG conjugated protein A or G beads. After 1/10 volume was removed as input, the precleared solution was incubated with specific antibodies overnight and then incubated with salmon sperm DNA and protein A or G beads for 1 h. 
RNA IP
After the IP products were washed, RNA elution buffer (100 mM Tris-Cl, 10 mM Na 2 -EDTA, 1% SDS, DPEC-H 2 O) was added to the IP products and they were further treated with Trizol to purify the pulled-down RNA. If DNA contamination were present, DNase I (RNase free) would be used to treat the RNA, and a second round of Trizol purification would be performed to exclude the DNase I enzyme. RT-PCR was performed to detect the specifically precipitated RNA.
IP and western blotting
Cells were lysed with IP lysis buffer (50 mM Tris-HCl, pH 7.2, 50 mM NaCl, 1% NP-40, 1 mM EDTA, 2% glycerol, 19 Complete). The lysates were incubated on ice for 30 min and centrifuged at 14 000 g for 10 min at 4°C. The supernatants were transferred to fresh tubes and the pellets were added with IP lysis buffer and then subjected to sonication followed by a second round of centrifugation at 12 000 rpm for 10 min at 4°C. The supernatants from the two extraction steps were pooled and incubated with the indicated protein G sepharose (GE Healthcare, Pittsburgh, PA, USA) which was pretreated with antibody overnight at 4°C. IP products were washed with cold IP and PBST buffers 5-10 times (0.5 mL per wash). Western blotting was performed using the standard method to detect the pulled-down protein.
The antibodies used in this study were as follows: rabbit anti-GAPDH, mouse anti-FLAG, rabbit anti-GFP, mouse anti-RNAPII, and mouse anti-Tat (Abcam, Cambridge, MA, USA); anti-rabbit Igs HRP (eBioscience, San Diego, CA, USA); rabbit and mouse IgG Trueblot, rat anti-AID and mouse IgG1 isotype control (eBioscience); anti-human Rrp40 and Mtr3 (Genway, San Diego, CA, USA).
Quantitative PCR and RT-PCR
The primers used in this study are shown in Table S1 . HBV DNA was extracted from the cells or from the medium using a QIAamp minikit (QIAGEN, Hilden, Germany) according to the manufacturer's protocol. Total RNA was extracted from cells using Trizol (Invitrogen) according to the manufacturer's instructions. The RNA obtained was dissolved in 100 lL DEPC-H 2 O and treated with DNase I (TAKARA, Dalian, China) for 10 min at 37°C, followed by a second round of Trizol purification. Next, 1 lg of purified RNA was re-treated with DNaseI (Invitrogen, Amplification Grade) for 10-15 min at room temperature, and DNase I activity was denatured according to the manufacturer's instructions. The RNA was immediately primed with oligodT or random primers and reverse-transcribed using Superscript III Reverse Transcriptase (Invitrogen). The real-time PCR Analysis was performed using the D-DCT method.
Vector information
The overexpression constructs of GFP-Tagged AID, P19, P20, and A3G were donated by Masamichi Muramatsu [20, 22] . HIV-1 vector pNL4.3, pNL4.3.Luc, pNL4.3.ΔE-GFP and HA-Tat, Vif expression constructs were donated by Guangxia Gao [38] .
Primer information
Primers are described in Table S1 .
Statistical analysis
Differences were tested using the two-tailed unpaired Student's t-test and were considered significant when P < 0.05.
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